Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage pharmaceutical company developing proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. The ARTL news feed on Stock Titan aggregates company announcements, scientific updates, financing transactions, and regulatory disclosures that shape the outlook for its drug development programs.
Investors and observers following Artelo’s news can track progress across a diversified pipeline that includes ART27.13 for cancer anorexia and weight loss, ART26.12 as a Fatty Acid Binding Protein 5 (FABP5) inhibitor for chemotherapy-induced peripheral neuropathy and other potential indications, and ART12.11, a patented cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Company press releases highlight interim clinical data from the Cancer Appetite Recovery Study (CAReS), Phase 1 results for ART26.12, and preclinical findings supporting the therapeutic potential of FABP inhibition and pharmaceutical-grade CBD formulations.
The ARTL news stream also features peer-reviewed publication announcements, conference presentations at oncology and cannabinoid-focused meetings, and corporate developments such as executive appointments, cooperation agreements with shareholders, and capital-raising activities via public offerings, private placements, and at-the-market programs. Regulatory and listing-related updates, including communications about Nasdaq listing compliance, are disclosed through Form 8-K filings and associated press releases.
By reviewing Artelo Biosciences news on this page, readers can monitor key milestones in its clinical trials, scientific validation of its FABP and CBD platforms, and corporate actions that influence its financial and strategic position. Bookmark this feed to follow how Artelo’s lipid-signaling and endocannabinoid-targeted programs evolve through clinical, scientific, and capital markets events over time.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has completed its previously announced public offering, raising $2.0 million in gross proceeds. The offering consisted of 441,210 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 13,335 shares at $4.399 per warrant.
The company has granted underwriters a 45-day option to purchase up to an additional 68,181 shares to cover over-allotments. R.F. Lafferty & Co. served as the sole book-running manager for the offering, which was conducted under Artelo's existing shelf registration statement.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the pricing of a $2.0 million public offering. The offering consists of 441,210 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 13,335 shares at $4.399 per warrant.
The company has granted underwriters a 45-day option to purchase up to an additional 68,181 shares. The offering, managed by R.F. Lafferty & Co. as the sole book-runner, is expected to close on October 1, 2025. The securities are being offered through a shelf registration statement previously filed with and declared effective by the SEC.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced a proposed underwritten public offering of common stock and/or pre-funded warrants. The offering will be managed by R.F. Lafferty & Co., Inc. as the sole book-running manager.
The securities will be offered through a "shelf" registration statement on Form S-3 that was previously filed and declared effective by the SEC on July 14, 2023. The final terms, size, and completion of the offering will depend on market conditions.
Artelo Biosciences (Nasdaq: ARTL) presented positive interim Phase 2 CAReS data for ART27.13 at the 2025 Cancer Cachexia Society Conference. The drug, targeting cancer anorexia-cachexia syndrome (CACS), demonstrated significant benefits in key metrics:
Patients receiving the highest dose (1300 µg) achieved an average +6% weight gain over 12 weeks, while placebo patients lost ~5%. The treatment showed improvements in lean body mass and increased daily activity levels, confirmed through digital wearable data. The drug maintained a favorable safety profile with mostly mild to moderate adverse events and no serious drug-related incidents.
Professor Barry Laird from Oslo University Hospital presented the data, while the company engaged in partnering discussions to advance the program's commercial potential.
Artelo Biosciences (Nasdaq: ARTL) has published significant preclinical data for ART12.11, their proprietary CBD:TMP cocrystal, demonstrating superior efficacy in treating stress-induced depression and anxiety compared to CBD alone. The study, published in Progress in Neuro-Psychopharmacology and Biological Psychiatry, revealed that ART12.11 achieved higher plasma concentrations and enhanced activation of endocannabinoid and serotonergic systems in key brain regions.
The research, conducted with Western Ontario University, showed ART12.11 reversed stress-induced behavioral deficits more effectively than CBD alone, TMP alone, or their non-crystalline mixture. Importantly, the MHRA has agreed to allow Artelo to leverage existing CBD and TMP data for their clinical trial application, potentially accelerating the pathway to human trials planned for next year.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has completed its previously announced public offering, raising $3.0 million in gross proceeds. The offering consisted of 640,924 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase 40,894 shares at $4.399 per warrant.
The company granted underwriters a 45-day option to purchase up to an additional 102,272 shares to cover over-allotments. R. F. Lafferty & Co. served as the sole book-running manager for the offering, which was conducted under Artelo's shelf registration statement.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the pricing of a $3.0 million public offering. The offering consists of 640,924 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at $4.399 per warrant.
The company has granted underwriters a 45-day option to purchase up to an additional 102,272 shares. R.F. Lafferty & Co. is serving as the sole book-running manager. The offering, expected to close on September 5, 2025, is being made through a shelf registration statement previously filed with the SEC.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the commencement of an underwritten public offering of common stock and/or pre-funded warrants. The offering will be managed by R.F. Lafferty & Co., Inc. as the sole book-running manager.
The securities will be offered through a "shelf" registration statement previously filed with the SEC (File No. 333-273153) and declared effective on July 14, 2023. The company focuses on developing treatments for cancer, pain, dermatologic, and neurological conditions through lipid-signaling pathway modulation.
Artelo Biosciences (Nasdaq: ARTL) has announced positive interim Phase 2 CAReS trial results for ART27.13, their treatment candidate for cancer anorexia-cachexia syndrome (CACS). The trial demonstrated significant improvements in weight, lean body mass, and activity in treated patients.
CACS affects up to 80% of cancer patients and currently has no FDA-approved treatment. Following these promising results and strong interest from multiple pharmaceutical companies, Artelo is actively pursuing partnership opportunities for ART27.13's development, stating they won't need to internally fund Phase 3 trials.
The company believes a licensing transaction represents the most value-accretive path forward for shareholders in this multi-billion-dollar potential market.
Artelo Biosciences (Nasdaq: ARTL) announced encouraging interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial for ART27.13, a treatment for cancer anorexia-cachexia syndrome (CACS). The study showed significant positive outcomes, with patients receiving the 1300 microgram dose achieving a +6.38% mean weight gain after 12 weeks, compared to -5.42% loss in placebo group.
Key highlights include a +4.23% increase in lean body mass at one month for treated patients, while placebo patients lost -3.15%. The drug demonstrated a favorable safety profile with mostly mild to moderate adverse events. The positive results are accelerating Artelo's partnering discussions with pharmaceutical companies for ART27.13, which targets CACS, a condition affecting up to 80% of cancer patients with no current FDA-approved treatment.